These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 2319306)
1. Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by intracarotid infusion of the neurotoxin MPTP. Palombo E; Porrino LJ; Bankiewicz KS; Crane AM; Sokoloff L; Kopin IJ J Neurosci; 1990 Mar; 10(3):860-9. PubMed ID: 2319306 [TBL] [Abstract][Full Text] [Related]
2. Changes in local cerebral glucose utilization associated with Parkinson's syndrome induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the primate. Porrino LJ; Burns RS; Crane AM; Palombo E; Kopin IJ; Sokoloff L Life Sci; 1987 Apr; 40(17):1657-64. PubMed ID: 3494179 [TBL] [Abstract][Full Text] [Related]
3. Changes in the local cerebral metabolic rate for glucose in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model of Parkinson's disease. Schwartzman RJ; Alexander GM Brain Res; 1985 Dec; 358(1-2):137-43. PubMed ID: 3878182 [TBL] [Abstract][Full Text] [Related]
4. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Mitchell IJ; Clarke CE; Boyce S; Robertson RG; Peggs D; Sambrook MA; Crossman AR Neuroscience; 1989; 32(1):213-26. PubMed ID: 2586750 [TBL] [Abstract][Full Text] [Related]
5. Hemiparkinsonism in monkeys following unilateral common carotid artery infusion of MPTP. A study of behavior, biochemistry and histology. Chen SD; Zhou XD; Xu DL; Li GW; Tang QM; Xu XR Chin Med J (Engl); 1991 Sep; 104(9):758-63. PubMed ID: 1935358 [TBL] [Abstract][Full Text] [Related]
6. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes. Oiwa Y; Eberling JL; Nagy D; Pivirotto P; Emborg ME; Bankiewicz KS Front Biosci; 2003 Sep; 8():a155-66. PubMed ID: 12957824 [TBL] [Abstract][Full Text] [Related]
7. MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys. Miletich RS; Bankiewicz KS; Quarantelli M; Plunkett RJ; Frank J; Kopin IJ; Di Chiro G Ann Neurol; 1994 Jun; 35(6):689-97. PubMed ID: 8210225 [TBL] [Abstract][Full Text] [Related]
8. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Mochizuki H; Imai H; Endo K; Yokomizo K; Murata Y; Hattori N; Mizuno Y Neurosci Lett; 1994 Feb; 168(1-2):251-3. PubMed ID: 8028787 [TBL] [Abstract][Full Text] [Related]
9. Administration of MPTP acutely increases glucose utilization in the substantia nigra of primates. Palombo E; Porrino LJ; Bankiewicz KS; Crane AM; Kopin IJ; Sokoloff L Brain Res; 1988 Jun; 453(1-2):227-34. PubMed ID: 3261197 [TBL] [Abstract][Full Text] [Related]
10. Local cerebral metabolic effects of L-dopa therapy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. Porrino LJ; Burns RS; Crane AM; Palombo E; Kopin IJ; Sokoloff L Proc Natl Acad Sci U S A; 1987 Aug; 84(16):5995-9. PubMed ID: 3497401 [TBL] [Abstract][Full Text] [Related]
11. In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis. Skirboll S; Wang J; Mefford I; Hsiao J; Bankiewicz KS Exp Neurol; 1990 Nov; 110(2):187-93. PubMed ID: 1699780 [TBL] [Abstract][Full Text] [Related]
12. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Pifl C; Schingnitz G; Hornykiewicz O Neuroscience; 1991; 44(3):591-605. PubMed ID: 1754053 [TBL] [Abstract][Full Text] [Related]
13. N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: neurochemical pathology and regional brain metabolism. Mitchell IJ; Cross AJ; Sambrook MA; Crossman AR J Neural Transm Suppl; 1986; 20():41-6. PubMed ID: 3462325 [TBL] [Abstract][Full Text] [Related]
14. Motor and nonmotor behavioral deficits in monkeys made hemiparkinsonian by intracarotid MPTP infusion. Schneider JS; McLaughlin WW; Roeltgen DP Neurology; 1992 Aug; 42(8):1565-72. PubMed ID: 1641154 [TBL] [Abstract][Full Text] [Related]
15. Cerebral metabolism of parkinsonian primates 21 days after MPTP. Schwartzman RJ; Alexander GM; Ferraro TN; Grothusen JR; Stahl SM Exp Neurol; 1988 Dec; 102(3):307-13. PubMed ID: 3264247 [TBL] [Abstract][Full Text] [Related]
16. Hemiparkinsonism in monkeys after unilateral caudate nucleus infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior and histology. Imai H; Nakamura T; Endo K; Narabayashi H Brain Res; 1988 Dec; 474(2):327-32. PubMed ID: 3264746 [TBL] [Abstract][Full Text] [Related]
17. Unilateral MPTP-induced parkinsonism in monkeys. A quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites. Przedborski S; Jackson-Lewis V; Popilskis S; Kostic V; Levivier M; Fahn S; Cadet JL Neurochirurgie; 1991; 37(6):377-82. PubMed ID: 1780015 [TBL] [Abstract][Full Text] [Related]
18. Intracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration: biochemical and behavioral observations in a primate model of hemiparkinsonism. Guttman M; Fibiger HC; Jakubovic A; Calne DB J Neurochem; 1990 Apr; 54(4):1329-34. PubMed ID: 1690267 [TBL] [Abstract][Full Text] [Related]
19. Antiparkinsonian and behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian primates. Wichmann T; Kliem MA; DeLong MR Exp Neurol; 2001 Feb; 167(2):410-24. PubMed ID: 11161630 [TBL] [Abstract][Full Text] [Related]